Compare Abeona Therapeutics Inc (ABEO) vs Accenture plc (ACN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Accenture plc — how do they compare? Abeona Therapeutics Inc trades at $7.57 (market cap $421.19M), while Accenture plc trades at $178.96 (market cap $110.04B). The key difference: Accenture plc is far larger — about 261.3× Abeona Therapeutics Inc's market cap, and Accenture plc pays a 3.63% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | ACN | |
|---|---|---|
Market Cap | $421.19M | $110.04B |
Sector | Health | Technology |
52-Week High | $7.45 | $288.54 |
52-Week Low | $4.17 | $124.41 |
Enterprise Value | $276.10M | $108.26B |
Dividend Yield | — | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Accenture (ACN) trades at $179.82, up 2.33% in the last session, with a bullish technical outlook and strong fundamental performance. The stock exhibits robust revenue growth, with 2025 revenue reaching $69.67 billion and net income of $7.68 billion, supported by consistent earnings beats. Recent partnerships with TEPCO Solution Advance and AlphaSense highlight strategic AI initiatives, enhancing its consulting and digital transformation services.
The investment outlook is positive, driven by solid financials, a consensus price target of $189.77, and low debt. Risks include competitive pressures and macroeconomic sensitivity. Analyst sentiment is strongly bullish with 66% buy ratings, indicating confidence in continued growth and shareholder value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Accenture plc
Accenture PLC provides management and technology consulting services and solutions. The Company delivers a range of specialized capabilities and solutions to clients across all industries on a worldwide basis. Accenture operates a network of businesses provides consulting, technology, outsourcing, and alliances.
Read more on ACN →
